WFH/LinkedIn
Feb 28, 2026, 14:48
WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“WFH Statement: the WFH acknowledges BioMarin’s decision to discontinue ROCTAVIAN and the importance of this development for the hemophilia community.
We urge BioMarin and other gene therapy developers to continue rigorous long-term safety monitoring of all discontinued products, and to preserve and share relevant clinical data that can inform ongoing scientific understanding and support patient safety.
For the full WFH position and our emphasis on preserving data in the WFH Gene Therapy Registry, please read our complete statement here.”
Other articles about World Federation of Hemophilia on Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment